Mitochondrial Genome Editing to Treat Human Osteoarthritis—A Narrative Review
Abstract
:1. Introduction
2. Osteoarthritis
3. Implication of the Mitochondria in Osteoarthritis
4. Mitochondrial Genome Editing and Potential Treatments for Osteoarthritis
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Hunter, D.J.; March, L.; Chew, M. Osteoarthritis in 2020 and beyond: A Lancet Commission. Lancet 2021, 396, 1711–1712. [Google Scholar] [CrossRef]
- Quicke, J.G.; Conaghan, P.G.; Corp, N.; Peat, G. Osteoarthritis year in review 2021: Epidemiology and therapy. Osteoarthr. Cartil. 2022, 30, 196–206. [Google Scholar] [CrossRef] [PubMed]
- Liu-Bryan, R.; Terkeltaub, R. Emerging regulators of the inflammatory process in osteoarthritis. Nat. Rev. Rheumatol. 2015, 11, 35–44. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kapoor, M.; Martel-Pelletier, J.; Lajeunesse, D.; Pelletier, J.-P.; Fahmi, H. Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. Nat. Rev. Rheumatol. 2011, 7, 33–42. [Google Scholar] [CrossRef]
- Loeser, R.F.; Collins, J.A.; Diekman, B.O. Ageing and the pathogenesis of osteoarthritis. Nat. Rev. Rheumatol. 2016, 12, 412–420. [Google Scholar] [CrossRef] [Green Version]
- Sharma, L. Osteoarthritis of the knee. N. Engl. J. Med. 2021, 284, 51–59. [Google Scholar] [CrossRef]
- Martel-Pelletier, J.; Barr, A.J.; Cicuttini, F.M.; Conaghan, P.G.; Cooper, C.; Goldring, M.B.; Goldring, S.R.; Jones, G.; Teichtal, A.J.; Pelletier, J.-P. Osteoarthritis. Nat. Rev. Dis. Primers 2016, 2, 16072. [Google Scholar] [CrossRef] [Green Version]
- Jones, I.A.; Togashi, R.; Wilson, M.L.; Heckmann, N.; Vansgness, C.T., Jr. Intra-articular treatment options for knee osteoarthritis. Nat. Rev. Rheumatol. 2019, 15, 77–90. [Google Scholar] [CrossRef]
- Hunter, D.J.; Bierma-Zeinstra, S. Osteoarthritis. Lancet 2019, 393, 1745–1759. [Google Scholar] [CrossRef]
- Blanco, F.J.; Rego, I.; Ruiz-Romero, C. The role of mitochondria in osteoarthritis. Nat. Rev. Rheumatol. 2011, 7, 161–169. [Google Scholar] [CrossRef]
- Blanco, F.J.; Valdes, A.M.; Rego-Perez, I. Mitochondrial variations and the pathogenesis of osteoarthritis phenotypes. Nat. Rev. Rheumatol. 2018, 14, 327–340. [Google Scholar] [CrossRef] [PubMed]
- Taanman, J.W. The mitochondrial genome: Structure, transcription, translation and replication. Biochim. Biophys. Acta 1999, 1410, 103–123. [Google Scholar] [CrossRef] [Green Version]
- Bolduc, J.A.; Collins, J.A.; Loeser, R.F. Reactive oxygen species, aging and articular cartilage homeostasis. Free Radic. Biol. Med. 2019, 132, 73–82. [Google Scholar] [CrossRef]
- Henrotin, Y.; Bruckner, P.; Pujol, J.-P.L. The role of reactive oxygen species in homeostasis and degradation of cartilage. Osteoarthr. Cartil. 2003, 11, 747–755. [Google Scholar] [CrossRef] [Green Version]
- Hunter, D.J.; Eckstein, F. From joint anatomy to clinical outcomes in osteoarthritis and cartilage repair: Summary of the fifth annual osteoarthritis imaging workshop. Osteoarthr. Cartil. 2011, 19, 1263–1269. [Google Scholar] [CrossRef] [Green Version]
- Chan, F.K.; Lanas, A.; Scheiman, J.; Berger, M.F.; Nguyen, H.; Goldstein, J.L. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): A randomised trial. Lancet 2010, 376, 173–179. [Google Scholar] [CrossRef]
- Bijlsma, J.W.; Berenbaum, F.; Lafeber, F.P. Osteoarthritis: An ujpdate with relevance for clinical practice. Lancet 2011, 377, 2115–2126. [Google Scholar] [CrossRef]
- Zhou, S.; Cui, Z.; Urban, J.P. Factors influencing the oxygen concentration gradient from the synovial surface of articular cartilage to the cartilage-bone interface: A modeling study. Arthritis Rheum. 2004, 50, 3915–3924. [Google Scholar] [CrossRef]
- Lee, R.B.; Urban, J.P. Functional replacement of oxygen by other oxidants in articular cartilage. Arthritis Rheum. 2002, 46, 3190–3200. [Google Scholar] [CrossRef]
- Gavriilidis, C.; Miwa, S.; von Zglinicki, T.; Taylor, R.W.; Young, D.A. Mitochondrial dysfunction in osteoarthritis is associated with down-regulation of superoxide dismutase 2. Arthritis Rheum. 2013, 65, 378–387. [Google Scholar] [CrossRef]
- Heer, C.D.; Brenner, C. Letting off electrons to cope with metabolic stress. Nat. Metab. 2020, 2, 485–486. [Google Scholar] [CrossRef] [PubMed]
- Lee, R.B.; Urban, J.P. Evidence for a negative Pasteur effect in articular cartilage. Biochem. J. 1997, 321, 95–102. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mylotte, L.A.; Duffy, A.M.; Murphy, M.; O’Brien, T.; Samali, A.; Barry, F.; Szegezdi, A. Metabolic flexibility permits mesenchymal stem cell survival in an ischemic environment. Stem Cells 2008, 26, 1325–1336. [Google Scholar] [CrossRef] [PubMed]
- Giacomello, M.; Pyakurel, A.; Glytsou, C.; Scorrano, L. The cell biology of mitochondrial membrane dynamics. Nat. Rev. Mol. Cell. Biol. 2020, 21, 204–224. [Google Scholar] [CrossRef] [PubMed]
- Chan, D.C. Mitochondrial dynamics and its involvement in disease. Annu. Rev. Pathol. 2020, 15, 235–259. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Szabo, I.; Zoratti, M. Mitochondrial channels: Ion fluxes and more. Physiol. Rev. 2014, 94, 519–608. [Google Scholar] [CrossRef]
- Andrews, R.M.; Kubacka, I.; Chinnery, P.F.; Lightowlers, R.N.; Turnbull, D.M.; Howell, N. Reanalysis and revision of the Cambridge reference sequence for human mitochondrial DNA. Nat. Genet. 1999, 23, 147. [Google Scholar] [CrossRef]
- Anderson, S.; Bankier, A.T.; Barrell, B.G.; de Bruijn, M.H.; Coulson, A.R.; Drouin, J.; Eperon, I.C.; Nierlich, D.P.; Roe, B.A.; Sanger, F.; et al. Sequence and organization of the human mitochondrial genome. Nature 1981, 290, 457–465. [Google Scholar] [CrossRef]
- Holt, I.J.; Harding, A.E.; Petty, R.K.; Morgan-Hughes, J.A. A new mitochondrial disease associated with mitochondrial DNA heteroplasmy. Am. J. Hum. Genet. 1990, 46, 428–433. [Google Scholar]
- Tatuch, Y.; Christodoulou, J.; Feigenbaum, A.; Clarke, J.T.; Wherret, J.; Smith, C.S.; Rudd, N.; Petrova-Benedict, R.; Robinson, B.H. Heteroplasmic mtDNA mutation (T----G) at 8993 can cause Leigh disease when the percentage of abnormal mtDNA is high. Am. J. Hum. Genet. 1992, 50, 852–858. [Google Scholar]
- Larsen, N.B.; Rasmussen, M.; Rasmussen, L.J. Nuclear and mitochondrial DNA repair: Similar pathways? Mitochondrion 2005, 5, 89–108. [Google Scholar] [CrossRef] [PubMed]
- Fontana, G.A.; Gahlon, H.L. Mechanisms of replication and repair in mitochondrial DNA deletion formation. Nucleic Acids Res. 2020, 48, 11244–11258. [Google Scholar] [CrossRef]
- Gorman, G.S.; Chinnery, P.F.; DiMauro, S.; Hirano, M.; Koga, Y.; McFarland, R.; Suomalainen, A.; Thorburn, D.R.; Zeviani, M.; Turnbull, D.M. Mitochondrial diseases. Nat. Rev. Dis. Primers 2016, 2, 16080. [Google Scholar] [CrossRef] [PubMed]
- Maneiro, E.; Martín, M.A.; de Andres, M.C.; López-Armada, M.J.; Fernández-Sueiro, J.L.; del Hoyo, P.; Galdo, F.; Arenas, J.; Blanco, F.J. Mitochondrial respiratory activity is altered in osteoarthritic human articular chondrocytes. Arthritis Rheum. 2003, 48, 700–708. [Google Scholar] [CrossRef] [PubMed]
- Ruiz-Romero, C.; Calamia, V.; Mateos, J.; Carreira, V.; Martínez-Gomariz, M.; Fernández, M.; Blanco, F.J. Mitochondrial dysregulation of osteoarthritic human articular chondrocytes analyzed by proteomics: A decrease in mitochondrial superoxide dismutase points to a redox imbalance. Mol. Cell Proteom. 2009, 8, 172–189. [Google Scholar] [CrossRef] [Green Version]
- Gorman, G.S.; Schaefer, A.M.; Ng, Y.; Gomez, N.; Blakely, E.L.; Alston, C.L.; Feeney, C.; Horvath, R.; Yu-Wai-Man, P.; Chinnery, P.F.; et al. Prevalence of nuclear and mitochondrial DNA mutations related to adult mitochondrial disease. Ann. Neurol. 2015, 77, 753–759. [Google Scholar] [CrossRef] [Green Version]
- Grishko, V.I.; Ho, R.; Wilson, G.L.; Pearsall, A.W., IV. Diminished mitochondrial DNA integrity and repair capacity in OA chondrocytes. Osteoarthr. Cartil. 2009, 17, 107–113. [Google Scholar] [CrossRef] [Green Version]
- Kim, J.; Xu, M.; Xo, R.; Mates, A.; Wilson, G.L.; Pearsall, A.W., IV. Mitochondrial DNA damage is involved in apoptosis caused by pro-inflammatory cytokines in human OA chondrocytes. Osteoarthr. Cartil. 2010, 18, 424–432. [Google Scholar] [CrossRef] [Green Version]
- Chang, M.C.; Hung, S.C.; Chen, W.Y.; Chen, T.L.; Lee, C.F.; Lee, H.C.; Wang, K.L.; Chiou, C.C.; Wei, Y.H. Accumulation of mitochondrial DNA with 4977-bp deletion in knee cartilage—an association with idiopathic osteoarthritis. Osteoarthr. Cartil. 2005, 13, 1004–1011. [Google Scholar] [CrossRef] [Green Version]
- Taylor, R.W.; Wardell, T.M.; Smith, P.M.; Muratovska, M.P.; Turnbull, D.M.; Lightowlers, R.N. An antigenomic strategy for treating heteroplasmic mtDNA disorders. Adv. Drug Deliv. Rev. 2001, 49, 121–125. [Google Scholar] [CrossRef]
- Chinnery, P.F.; Taylor, R.W.; Diekert, K.; Lill, R.; Turnbull, D.M.; Lighowlers, R.N. Peptide nucleic acid delivery to human mitochondria. Gene Ther. 1999, 6, 1919–1928. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Muratovska, A.; Lightowlers, R.N.; Taylor, R.W.; Turnbull, D.M.; Smith, R.A.; Wilce, J.A.; Martin, S.W.; Murphy, M.P. Targeting peptide nucleic acid (PNA) oligomers to mitochondria withing cells by conjugation to lipophilic cations: Implications for mitochondrial DNA replication, expression and disease. Nucleic Acids Res. 2001, 29, 1852–1863. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tonin, Y.; Heckel, A.M.; Vysokikh, M.; Dovydenko, I.; Meschaninova, M.; Rötig, A.; Munnich, A.; Venyaminova, A.; Tarassov, I.; Entelis, N. Modeling of antigenomic therapy of mitochondrial diseases by mitochondrially addressed RNA targeting a pathogenic point mutation in mitochondrial DNA. J. Biol. Chem. 2014, 289, 13323–13334. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Costa, N.D.; Thacker, J. The efficiency of restriction endonuclease digests determind by PCR. Biotechniques 1992, 13, 190. [Google Scholar] [PubMed]
- Bayona-Bafaluy, M.P.; Blits, B.; Battersby, B.J.; Shoubridge, E.A.; Moraes, C.T. Rapid directional shift of mitochondrial DNA heteroplasmy in animal tissues by a mitochondrially targeted restriction endonuclease. Proc. Natl. Acad. Sci. USA 2005, 102, 14392–14397. [Google Scholar] [CrossRef] [Green Version]
- Bacman, S.R.; Williams, S.L.; Moraes, C.T. Manipulation of mtDNA heteroplasmy in all striated muscles of newborn mice by AAV9-mediated delivery of a mitochondria-targeted restriction endonuclease. Gene Ther. 2012, 19, 1101–1106. [Google Scholar] [CrossRef] [Green Version]
- Bacman, S.R.; Williams, S.L.; Garcia, S.; Moraes, C.T. Organ-specific shifts in mtDNA heteroplasmy following systemic delivery of a mitochondria-targeted restriction endonuclease. Gene Ther. 2010, 17, 713–720. [Google Scholar] [CrossRef]
- Srivastava, S.; Moraes, C.T. Manipulating mitochondrial DNA heteroplasmy by a mitochondrially targeted restriction endonuclease. Hum. Mol. Genet. 2001, 10, 3093–3099. [Google Scholar] [CrossRef] [Green Version]
- Baracca, A.; Barogi, S.; Carelli, V.; Lenaz, G.; Solaini, G. Catalytic activities of mitochondrial ATP synthase in patients with mitochondrial DNA T8993G mutation in the ATPase 6 gene encoding subunit a. J. Biol. Chem. 2000, 275, 4177–4182. [Google Scholar] [CrossRef] [Green Version]
- Sgarbi, G.; Baracca, A.; Lenaz, G.; Valentino, L.M.; Carelli, V.; Solaini, G. Inefficient coupling between proton transport and ATP synthesis may be the pathogenic mechanism for NARP and Leigh syndrome resulting from the T8993G mutation in mtDNA. Biochem. J. 2006, 395, 493–500. [Google Scholar] [CrossRef] [Green Version]
- Tanaka, M.; Borgeld, H.J.; Zhang, J.; Muramatsu, S.; Gong, J.S.; Yoneda, M.; Maruyama, W.; Naoi, M.; Ibi, T.; Sahashi, K.; et al. Gene therapy for mitochondrial disease by delivering restriction endonuclease SmaI into mitochondria. J. Biomed. Sci. 2002, 9, 534–541. [Google Scholar] [PubMed]
- Urnov, F.D.; Rebar, E.J.; Holmes, M.C.; Zhang, H.S.; Gregory, P.D. Genome editing with engineered zinc finger nucleases. Nat. Rev. Genet. 2010, 11, 636–646. [Google Scholar] [CrossRef] [PubMed]
- Minczuk, M.; Papworth, M.A.; Kolasinska, P.; Murphy, M.P.; Klug, A. Sequence-specific modification of mitochondrial DNA using a chimeric zinc finger methylase. Proc. Natl. Acad. Sci. USA 2006, 103, 19689–19694. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Minczuk, M.; Papworth, M.A.; Miller, J.C.; Murphy, M.P.; Klug, A. Development of a single-chain, quasi-dimeric zinc-finger nuclease for the selective degradation of mutated human mitochondrial DNA. Nucleic Acids Res. 2008, 36, 3926–3938. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gammage, P.A.; Gaude, E.; Van Haute, L.; Rebelo-Guiomar, P.; Jackson, C.B.; Rorbach, J.; Pekalski, M.L.; Robinson, A.J.; Charpentier, M.; Concordet, J.P.; et al. Near-complete elimination of mutant mtDNA by iterative or dynamic dose-controlled treatment with mtZFNs. Nucleic Acids Res. 2016, 44, 7804–7816. [Google Scholar] [CrossRef]
- Gammage, P.A.; Rorbach, J.; Vincent, A.I.; Rebar, E.J.; Minczuk, M. Mitochondrially targeted ZFNs for selective degradation of pathogenic mitochondrial genomes bearing large-scale deletions or point mutations. EMBO Mol. Med. 2014, 6, 458–466. [Google Scholar] [CrossRef]
- Gammage, P.A.; Viscomi, C.; Simard, M.L.; Costa, A.S.H.; Gaude, E.; Powell, C.A.; Van Haute, L.; McCann, B.J.; Rebelo-Guiomar, P.; Cerutti, R.; et al. Genome editing in mitochondria corrects a pathogenic mtDNA mutation in vivo. Nat. Med. 2018, 24, 1691–1695. [Google Scholar] [CrossRef]
- Szczepek, M.; Brondani, V.; Büchel, J.; Serrano, L.; Segal, D.J.; Cathomen, T. Structure-based redesign of the dimerization interface reduces the toxicity of zinc-finger nucleases. Nat. Biotechnol. 2007, 25, 786–793. [Google Scholar] [CrossRef]
- Pruett-Miller, S.M.; Connelly, J.P.; Maeder, M.L.; Joung, J.K.; Porteus, M.H. Comparison of zinc finger nucleases for use in gene targeting in mammalian cells. Mol. Ther. 2008, 16, 707–717. [Google Scholar] [CrossRef]
- Pereira, C.V.; Moraes, C.T. Current strategies towards therapeutic manipulation of mtDNA heteroplasmy. Front. Biosci. (Landmark Ed.) 2017, 22, 991–1010. [Google Scholar]
- Deng, D.; Yan, C.; Pan, X.; Mahfouz, M.; Wang, J.; Zhu, J.K.; Shi, Y.; Yan, N. Structural basis for sequence-specific recognition of DNA by TAL effectors. Science 2012, 335, 720–723. [Google Scholar] [CrossRef] [Green Version]
- Qasim, W.; Zhan, H.; Samarasinghe, S.; Adams, S.; Amrolia, P.; Stafford, S.; Butler, K.; Rivat, C.; Wright, G.; Somana, K.; et al. Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. Sci. Transl. Med. 2017, 9, 1–8. [Google Scholar] [CrossRef] [PubMed]
- Miller, J.C.; Tan, S.; Qiao, G.; Barlow, K.A.; Wang, J.; Xia, D.F.; Meng, X.; Paschon, D.E.; Leung, E.; Hinkley, S.J.; et al. A TALE nuclease architecture for efficient genome editing. Nat. Biotechnol. 2011, 29, 143–148. [Google Scholar] [CrossRef] [PubMed]
- Jun, A.S.; Trounce, I.A.; Brown, M.D.; Shoffner, J.M.; Wallace, D.C. Use of transmitochondrial cybrids to assign a complex I defect to the mitochondrial DNA-encoded NADH dehydrogenase subunit 6 gene mutation at nucleotide pair 14459 that causes Leber hereditary optic neuropathy and dystonia. Mol. Cell Biol. 1996, 16, 771–777. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bacman, S.R.; Williams, S.L.; Pinto, M.; Peralta, S.; Moraes, C.T. Specific elimination of mutant mitochondrial genomes in patient-derived cells by mitoTALENs. Nat. Med. 2013, 19, 1111–1113. [Google Scholar] [CrossRef] [PubMed]
- Hashimoto, M.; Bacman, S.R.; Peralta, S.; Falk, M.J.; Chomyn, A.; Chan, D.C.; Williams, S.L.; Moraes, C. MitoTALEN: A general approach to reduce mutant mtDNA loads and restore oxidative phosphorylation function in mitochondrial diseases. Mol. Ther. 2015, 23, 1592–1599. [Google Scholar] [CrossRef] [Green Version]
- Pereira, C.V.; Bacman, S.R.; Arguello, T.; Zekonyte, U.; Williams, S.L.; Edgell, D.R.; Moraes, C.T. mitoTev-TALE: A monomeric DNA editing enzyme to reduce mutant mitochondrial DNA levels. EMBO Mol. Med. 2018, 10, e8084. [Google Scholar] [CrossRef]
- Yahata, N.; Matsumoto, Y.; Omi, M.; Yamamoto, N.; Hata, R. TALEN-mediated shift of mitochondrial DNA heteroplasmy in MELAS-iPSCs with m.13513G>A mutation. Sci. Rep. 2017, 7, 15557. [Google Scholar] [CrossRef] [Green Version]
- Yang, Y.; Wu, H.; Kang, X.; Liang, Y.; Lan, T.; Li, T.; Tan, T.; Peng, J.; Zhang, Q.; An, G.; et al. Targeted elimination of mutant mitochondrial DNA in MELAS-iPSCs by mitoTALENs. Protein. Cell 2018, 9, 283–297. [Google Scholar] [CrossRef] [Green Version]
- Mok, B.Y.; de Moraes, M.H.; Zeng, J.; Bosch, D.E.; Kotrys, A.V.; Raguram, A.; Hsu, F.; Radey, M.C.; Peterson, S.B.; Mootha, V.K.; et al. A bacterial cytidine deaminase toxin enables CRISPR-free mitochondrial base editing. Nature 2020, 583, 631–637. [Google Scholar] [CrossRef]
- Falkenberg, M.; Hirano, M. Editing the mitochondrial genome. N. Engl. J. Med. 2020, 383, 1489–1491. [Google Scholar] [CrossRef] [PubMed]
- Lee, H.; Lee, S.; Baek, G.; Kim, A.; Kang, B.C.; Seo, H.; Kim, J.S. Mitochondrial DNA editing in mice with DddA-TALE fusion deaminases. Nat. Commun. 2021, 12, 1190–1195. [Google Scholar] [CrossRef] [PubMed]
- Jinek, M.; Chylinski, K.; Fonfara, I.; Hauer, M.; Doudna, J.A.; Charpentier, E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 2012, 337, 816–821. [Google Scholar] [CrossRef] [PubMed]
- Chylinski, K.; Makarova, K.S.; Charpentier, E.; Koonin, E.V. Classification and evolution of type II CRISPR-Cas systems. Nucleic Acids Res. 2014, 42, 6091–6105. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Porteus, M.H. A new class of medicines through DNA editing. N. Engl. J. Med. 2019, 380, 947–959. [Google Scholar] [CrossRef] [PubMed]
- Cyranoski, D. CRISPR gene-editing tested in a person for the first time. Nature 2016, 539, 479. [Google Scholar] [CrossRef]
- Stadtmauer, E.A.; Fraietta, J.A.; Davis, M.M.; Cohen, A.D.; Weber, K.L.; Lancaster, E.; Mangan, P.A.; Kulikovskaya, I.; Gupta, M.; Chen, F.; et al. CRISPR-engineered T cells in patients with refractory cancer. Science 2020, 367, 1–13. [Google Scholar] [CrossRef]
- The Lancet Haematology. CRISPR-Cas9 gene editing for patients with haemoglobinopathies. Lancet Haematol. 2019, 6, e438. [Google Scholar] [CrossRef]
- Xu, L.; Wang, J.; Liu, Y.; Xie, L.; Su, B.; Mou, D.; Wang, L.; Liu, T.; Wang, X.; Zhang, B.; et al. CRISPR-edited stem cells in a patient with HIV and acute lymphocytic leukemia. N. Engl. J. Med. 2019, 381, 1240–1247. [Google Scholar] [CrossRef]
- Jo, A.; Ham, S.; Lee, G.H.; Lee, Y.I.; Kim, S.; Lee, Y.S.; Shin, J.H.; Lee, Y. Efficient mitochondrial genome editing by CRISPR/Cas9. Biomed. Res. Int. 2015, 2015, 305716. [Google Scholar] [CrossRef] [Green Version]
- Gammage, P.A.; Moraes, C.T.; Minczuk, M. Mitochondrial genome engineering: The revolution may not be CRISPR-Ized. Trends Genet. 2018, 34, 101–110. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mahata, B.; Mukherjee, S.; Mishra, S.; Bandyopadhyay, A.; Adhya, S. Functional delivery of a cytosolic tRNA into mutant mitochondria of human cells. Science 2006, 314, 471–474. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Goswami, S.; Dhar, G.; Mukherjee, S.; Mahata, B.; Chatterjee, S.; Home, P.; Adhya, S. A bifunctional tRNA import receptor from Leishmania mitochondria. Proc. Natl. Acad. Sci. USA 2006, 103, 8354–8359. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Entelis, N.; Brandina, I.; Kamenski, P.; Krasheninnikov, I.A.; Martin, R.P.; Tarassov, I. A glycolytic enzyme, enolase, is recruited as a cofactor of tRNA targeting toward mitochondria in Saccharomyces cerevisiae. Genes Dev. 2006, 20, 1609–1620. [Google Scholar] [CrossRef] [Green Version]
- Moretton, A.; Morel, F.; Macao, B.; Lachaume, P.; Ishak, L.; Lefebvre, M.; Garreau-Balandier, I.; Vernet, P. Selective mitochondrial DNA degradation following double-strand breaks. PLoS ONE 2017, 12, e0176795. [Google Scholar] [CrossRef] [Green Version]
- Hagstrom, E.; Freyer, C.; Battersby, B.J.; Stewart, J.B.; Larsson, N.G. No recombination of mtDNA after heteroplasmy for 50 generations in the mouse maternal germline. Nucleic Acids Res. 2014, 42, 1111–1116. [Google Scholar] [CrossRef] [Green Version]
- Weinberg, S.E.; Sena, L.A.; Chandel, N.S. Mitochondria in the regulation of innate and adaptive immunity. Immunity 2015, 42, 406–417. [Google Scholar] [CrossRef] [Green Version]
- Filograna, R.; Koolmeister, C.; Upadhyay, M.; Pajak, A.; Clemente, P.; Wibom, R.; Simard, M.L.; Wredenberg, A.; Freyer, C.; Stewart, J.B.; et al. Modulation of mtDNA copy number ameliorates the pathological consequences of a heteroplasmic mtDNA mutation in the mouse. Sci. Adv. 2019, 5, eaav9824. [Google Scholar] [CrossRef] [Green Version]
- Rey-Rico, A.; Cucchiarini, M. Controlled release strategies for rAAV-mediated gene delivery. Acta Biomater. 2016, 29, 1–10. [Google Scholar] [CrossRef]
- Cucchiarini, M.; Madry, H. Biomaterial-guided delivery of gene vectors for targeted articular cartilage repair. Nat. Rev. Rheumatol. 2019, 15, 18–29. [Google Scholar] [CrossRef]
- Jiang, D.; Gao, F.; Zhang, Y.; Wong, D.S.; Li, Q.; Tse, H.F.; Xu, G.; Yu, Z.; Lian, Q. Mitochondrial transfer of mesenchymal stem cells effectively protects corneal epithelial cells from mitochondrial damage. Cell Death Dis. 2016, 7, e2467. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Types | Recognition Sites | Advantages | Limitations | Refs. |
---|---|---|---|---|
antigenomic mtDNA | antigenomic-BS | easy to design | large, limited target sites, poor specificity | [40,41,42,43] |
REs | RE-BS | easy to design | large, limited target sites, poor specificity | [44,45,46,47,48,49,50,51] |
ZFNs | ZFN-BS | small, highly specific | difficult to design, limited target sites | [52,53,54,55,56,57,58] |
TALENs | TALEN-BS | easy to design, highly specific | large, limited target sites | [60,61,62,63,64,65,66,67,68,69,70,71,72] |
CRISPR/Cas9 | CRISPR/Cas9-BS | easy to design | gRNA import, limited target sites | [80,82,83,84] |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Zhong, G.; Madry, H.; Cucchiarini, M. Mitochondrial Genome Editing to Treat Human Osteoarthritis—A Narrative Review. Int. J. Mol. Sci. 2022, 23, 1467. https://doi.org/10.3390/ijms23031467
Zhong G, Madry H, Cucchiarini M. Mitochondrial Genome Editing to Treat Human Osteoarthritis—A Narrative Review. International Journal of Molecular Sciences. 2022; 23(3):1467. https://doi.org/10.3390/ijms23031467
Chicago/Turabian StyleZhong, Gang, Henning Madry, and Magali Cucchiarini. 2022. "Mitochondrial Genome Editing to Treat Human Osteoarthritis—A Narrative Review" International Journal of Molecular Sciences 23, no. 3: 1467. https://doi.org/10.3390/ijms23031467